Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05625503 · ClinicalTrials.gov registry record · Early Phase 1

Dilution of Verapamil During Intraarterial Administration

A Early Phase 1 study of Pain and Vasospasm;Peripheral, sponsored by University of Illinois at Chicago.

Completed
Registry status
Early Phase 1
Development phase
55
Enrollment target
1
Study location

NCT05625503 is a Early Phase 1 study of Pain and Vasospasm;Peripheral that has completed, run by University of Illinois at Chicago. The registered enrollment target is 55 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05625503, a Early Phase 1 study of Pain and Vasospasm;Peripheral, has completed, sponsored by University of Illinois at Chicago.

COMPLETED
Registry status
Early Phase 1
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

This study will be a randomized, single-blind, prospective trial designed to evaluate the efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to undiluted IA Nicardipine during transradial access (TRA) for percutaneous coronary angiography. Patients who are 18 years or older and undergoing non-emergent percutaneous coronary angiography via TRA will be included. Patients who are non-English speaking, pregnant, or intubated will be excluded. Patients will be randomized to one of the two following groups: 1. Group 1 will receive IA Verapamil 5 mg (2mL) diluted with 8 mL of normal saline 2. Group 2 will receive IA Nicardipine 400 mcg (undiluted, 8 mL) The investigators will document the patient's level of discomfort on the Visual Analogue Scale 30 seconds before and after administration of IA Verapamil/Nicardipine. The investigators will also document the presence of radial artery spasms.

Conditions Studied

Pain Vasospasm;Peripheral Burning

Interventions

  • DRUG Verapamil
  • DRUG Nicardipine

Study Locations (1)

Illinois

  • University of Illinois Hospital - Chicago

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2022-12-13
Est. Completion 2023-12-01
Phase Early Phase 1

Sponsor

University of Illinois at Chicago

430 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05625503

The ClinicalTrials.gov registry entry for NCT05625503 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Verapamil is the first listed.

NCT05625503 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05625503 about?

NCT05625503 is a clinical study titled "Dilution of Verapamil During Intraarterial Administration". This study will be a randomized, single-blind, prospective trial designed to evaluate the efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to undiluted IA Nicardipine during transradial access (TRA) for percutaneous coronary angiography. Patients who are 18 ye...

What is the current status of trial NCT05625503?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 55 participants. The study started on 2022-12-13. Estimated completion is 2023-12-01.

What conditions does trial NCT05625503 study?

This clinical trial studies the following conditions: Pain, Vasospasm;Peripheral, Burning.

What interventions are being tested in trial NCT05625503?

The interventions under investigation include: Verapamil (DRUG), Nicardipine (DRUG).

Who is sponsoring clinical trial NCT05625503?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05625503 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pain

All registered trials for this condition

Vasospasm;Peripheral

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.